Deutsche Märkte geschlossen

MorphoSys AG (MOR.F)

Frankfurt - Frankfurt Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
20,88-0,37 (-1,74%)
Börsenschluss: 03:15PM CEST

MorphoSys AG

Semmelweisstrasse 7
Planegg 82152
49 89 89927 0


Leitende Angestellte

Dr. Jean-Paul Kress M.D.Chairman of Management Board, MD & CEO1,94MN/A1965
Mr. Sung H. LeeCFO & Member of Management Board488,7kN/A1970
Dr. Malte Peters M.D.Chief R&D Officer and Member of the Management Board1,15MN/A1962
Dr. Marlies SprollSpecial Adviser to the Chief Exec. OfficerN/AN/A1958
Mr. Klaus De WallHead of Accounting & TaxN/AN/AN/A
Ms. Lara Smith WeberHead of Controlling, Corp. Fin. & Corp. Devel.N/AN/AN/A
Dr. Margit UrbanHead of Discovery Alliances & TechnologiesN/AN/AN/A
Dr. Anja PomrehnSr. VP & Head of Investor RelationsN/AN/AN/A
Ms. Charlotte LohmannSr. VP of Legal, Compliance & IP and Gen. CounselN/AN/A1970
Mr. Thomas BiegiVP & Head of Corp. CommunicationsN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.


MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Corporate Governance

MorphoSys AGs ISS Governance QualityScore, Stand 31. Juli 2022, lautet 1. Die grundlegenden Scores sind Audit: 5, Vorstand: 1, Shareholderrechte: 1, Kompensation: 2.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.